# Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

> **NCT00657488** · PHASE2,PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 400 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00657488
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12-01
- **Primary completion:** 2005-10-01
- **Final completion:** 2006-04-01
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657488, "Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00657488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*